Navigation Links
Preclinical tests shows agent stops 'slippery' proteins from binding, causing Ewing sarcoma
Date:5/15/2013

WASHINGTON Continuous infusion of a novel agent not only halted the progression of Ewing sarcoma in rats, while some tumors also regressed to the point that cancer cells could not be detected microscopically, say researchers at Georgetown Lombardi Comprehensive Cancer Center. Their study, which will be presented at the 2013 annual meeting of the American Society of Clinical Oncology, provides pre-clinical evidence necessary to initiate a clinical trial.

"This agent has the potential to be more effective, and considerably less toxic, than the current drugs now used to treat this rare cancer," says the study's lead investigator, Jeffrey Toretsky, MD, a pediatric oncologist and researcher at Georgetown Lombardi, part of Georgetown University Medical Center.

The agent, (S)-YK-4-279, was developed by Toretsky and his colleagues, including scientists in GUMC's Center for Drug Discovery. Based on early promising studies of the compound, Toretsky established TDP Biotherapeutics, Inc. to manufacture the agent. Toretsky says TDP Biotherapeutics, Inc. is preparing a U.S. Food and Drug Administration (FDA) investigational new drug (IND) application for (S)-YK-4-279 so that a clinical trial can be initiated.

In the United States, about 500 children and young adults are diagnosed with the cancer annually, and they are treated with a combination of five different chemotherapy drugs. Between 60 to 70 percent of patients survive more than five years, but with many late effects from therapy. Few treatments lead to a cure for patients whose cancer progresses, Toretsky says.

Ewing sarcoma is caused by the exchange of DNA between two chromosomes. The resulting EWSR1-FLI1 gene produces a fusion protein, EWS-FLI1, responsible for development of the cancer. In 2006, Toretsky and his team discovered that the fusion protein binds to another protein, RNA helicase A (RHA), which is important for cancer progression.

The (S)-YK-4-279 agent they deve
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
2. Genetically-engineered preclinical models predict pharmacodynamic response
3. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
4. Charm Sciences Announces Six WET® (Water Extraction Technology) Mycotoxin Tests
5. Half of People With Hepatitis C Dont Complete Needed Tests: CDC
6. All hospitals should require drug, alcohol tests for physicians
7. Consumer Reports Tests: Bacteria on Turkey Raised Without Antibiotics Showed Significantly Less Antibiotic Resistance than Bacteria Conventional Turkey
8. Battery of tests on cancer cells shows them as squishy, yet tactically strong
9. PeopleKeys Personality Tests Give Job Seekers a Competitive Advantage
10. Doctors Order Fewer Lab Tests When They Know the Cost
11. Naturally-occurring substance proves effective against deadly skin cancer in laboratory tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... Center have published the first study to extensively ... The Journal of Allergy and Clinical Immunology ... that has high levels of eosinophils in the ... allergy-associated-immune mechanisms and has a gene expression pattern ... related disorder, eosinophilic esophagitis (EoE). , Eosinophilic ...
(Date:9/23/2014)... 23, 2014) Laparoscopic cholecystectomy, a minimally invasive procedure to ... abdominal surgeries in the U.S. Yet medical centers around ... with some moving patients quickly into surgery while others ... the American Journal of Surgery , researchers found ... rather than rushing the patients into the operating room ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... 2014 Royal Sport Ultra Clean 100 ... LTD family of premium sports nutrition products. Its gluten ... Whey protein without artificial colors or dyes, fillers, added ... available on shelves at select GNC retailers, on GNC.com, ... is offering a limited time special on its products. ...
Breaking Medicine News(10 mins):Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:Study finds gallbladder surgery can wait 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2
... intensive therapy works well, study finds , THURSDAY, Aug. ... (RA) who respond poorly to standard treatment with methotrexate ... (TNF) blockers, a Swedish study suggests. , Previous research ... patients have a good response to methotrexate therapy and ...
... , , MISSION VIEJO, Calif., ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care ... quarter of fiscal year 2009. , , (Logo: ... Include: , , Total revenue was ...
... , , RANCHO CORDOVA, Calif., ... ), a leading supplier of innovative products for processing and storing ... BMC ("Res-Q") System, an automated cell processing medical device for the ... , , The Res-Q System processes bone ...
... American Health Assistance Foundation Researcher Is Featured Facilitator , ... Health Assistance Foundation and Asbury Methodist Village are partnering to host a ... Project to bring awareness to the community about this devastating disease, ... Part one of the Momentum in Science ...
... ... The Angelman Syndrome Foundation, www.angelman.org , announced the ... direct the organization,s rapidly increasing research funding. The ATRI will also ... scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. ...
... BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- , ... CHDX ), a leading,independent American provider ... Republic of China, today announced that the Company,s,Western-style ... a comprehensive, international-standard oncology program, called "New,Hope," at ...
Cached Medicine News:Health News:TNF Blockers May Help Some With Rheumatoid Arthritis 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 3Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 4Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 5Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 6Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 7Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 8Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 9Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 10Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 11Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 12Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 13Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 2Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 3Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 2Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 3Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4
(Date:9/23/2014)... , Sept. 23, 2014 Research and ... "Biopharmaceutical and Vaccine Production Markets" report to their ... new therapies and vaccines - including products to treat ... still huge challenges during the final stages of clinical ... and how to risk production capital to upscale while ...
(Date:9/23/2014)... 23, 2014  SiteOne Therapeutics Inc. today announced the ... by Sears Capital Management and Biobrit LLC, with additional ... the $1.5 million financing positions SiteOne to advance its ... to further develop its technology platform for long-acting local ... In conjunction with the financing, Lowell Sears ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... Laserex Tango ophthalmic laser system provides two ... laser and a photodisruptor for posterior capsulotomy ... frequency-doubled Nd:YAG producing pulsed 532 nm light. ... 1064 nm. The appropriate laser can be ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Flat handle cross action....
Medicine Products: